(51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained ...
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic... CSL ...
Melbourne, Tuesday 2 December 2025 – Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing, opened CSL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback